Core Viewpoint - Shenwei Pharmaceutical (02877.HK) reported a significant decline in revenue and gross profit for the fiscal year 2025, reflecting challenges in the traditional Chinese medicine industry due to various external pressures [1] Company Performance - Revenue for the year was RMB 3.135 billion, a decrease of 17.0% compared to the previous year [1] - Gross profit amounted to RMB 2.266 billion, down 20% year-on-year [1] - The profit attributable to shareholders increased by 13.1% to RMB 950 million [1] - Basic earnings per share were RMB 1.26, with a proposed interim dividend of RMB 0.43 per share for 2026 [1] Industry Context - The traditional Chinese medicine industry is undergoing a deep adjustment and value reconstruction period due to five major factors: medical insurance cost control, centralized procurement price reductions, shrinking demand, consumer downgrade, and rising production costs [1] - Overall sales in the industry have declined, with most product revenues experiencing significant decreases during the year [1]
神威药业(02877.HK)：2025年纯利为9.5亿元 同比增加13.1%